Should new therapies for MS be subjected to clinical trials even with poor scientific support Host: Olaf Stuve, USA Yes: Ralf Linker, Germany Are MS patients at increased risk for developing cancer?
Host: Cris Constantinescu, UK Yes: Ali Manouchehrinia, Sweden No: Melinda Magyari, Denmark Are the 2017 MS McDonald criteria too liberal and should be more restrictive?
Host: Ralf Linker, Germany Yes: Brian Weinshenker, USA No: Christopher Hawkes, UK Does OCT make VEP redundant?
Host: Abhijit Chauduri, UK Yes: Hadas Stiebel-Kalish, Israel No: Mario Habek, Croatia Newly diagnosed MS patients should be started on aggressive therapy
Host: Jera Kruja, Albania Yes: Ron Milo, Israel No: Uros Rot, Slovenia MS is a primary progressive disease in all cases, but some patients have superimposed relapses
Host: Bart van Wijmeersch, Belgium Yes: Antonio Scalfari, UK No: Bianca Weinstock-Guttman, USA In MS patients with significant cognitive decline, drug treatment should be modified.
Host: Thomas Berger, Austria Add a new agent: Ron Milo, Israel Not so fast: Amos Korczyn, Israel Cognitive decline is sufficient to define transition to secondary progressive multiple sclerosis (SPMS).
Host: Dimitrios Karussis, Israel Yes: Klaus Schmierer, UK No: Thomas Berger, Austria We are well enough equipped to identify fake news in MS therapy before it can cause harm.
Host: Nikos Evangelou, UK Yes: Klaus Schmierer, UK No: Radu Tanasescu, UK